

# KCNQ1 antibody - N-terminal region

Rabbit Polyclonal Antibody

Catalog # AI10761

## Product Information

<b>Application</b>	WB, IHC
<b>Primary Accession</b>	<a href="#">P51787</a>
<b>Other Accession</b>	<a href="#">NM_181797</a> , <a href="#">NP_861462</a>
<b>Reactivity</b>	Human, Mouse, Rat, Rabbit, Zebrafish, Dog, Horse, Bovine
<b>Predicted</b>	Human, Mouse, Rabbit, Pig, Chicken, Bovine
<b>Host</b>	Rabbit
<b>Clonality</b>	Polyclonal
<b>Calculated MW</b>	74699

## Additional Information

<b>Gene ID</b>	3784
<b>Alias Symbol</b>	ATFB1, FLJ26167, JLNS1, KCNA8, KCNA9, KVLQT1, Kv1.9, Kv7.1, LQT, LQT1, RWS, SQT2, WRS, ATFB3
<b>Other Names</b>	Potassium voltage-gated channel subfamily KQT member 1, IKs producing slow voltage-gated potassium channel subunit alpha KvLQT1, KQT-like 1, Voltage-gated potassium channel subunit Kv7.1, KCNQ1, KCNA8, KCNA9, KVLQT1
<b>Format</b>	Liquid. Purified antibody supplied in 1x PBS buffer with 0.09% (w/v) sodium azide and 2% sucrose.
<b>Reconstitution &amp; Storage</b>	Add 50 ul of distilled water. Final anti-KCNQ1 antibody concentration is 1 mg/ml in PBS buffer with 2% sucrose. For longer periods of storage, store at 20°C. Avoid repeat freeze-thaw cycles.
<b>Precautions</b>	KCNQ1 antibody - N-terminal region is for research use only and not for use in diagnostic or therapeutic procedures.

## Protein Information

<b>Name</b>	KCNQ1 ( <a href="#">HGNC:6294</a> )
<b>Function</b>	Pore-forming subunit of the voltage-gated potassium (Kv) channel involved in the regulation of cardiomyocyte excitability and important in normal development and functions of myocardium, inner ear, stomach and colon (PubMed: <a href="#">10646604</a> , PubMed: <a href="#">25441029</a> ). Associates with KCNE beta subunits that modulates current kinetics (PubMed: <a href="#">10646604</a> , PubMed: <a href="#">11101505</a> , PubMed: <a href="#">19687231</a> , PubMed: <a href="#">8900283</a> , PubMed: <a href="#">9108097</a> , PubMed: <a href="#">9312006</a> ). Induces a voltage-dependent current by rapidly activating and slowly

deactivating potassium-selective outward current (PubMed:[10646604](#), PubMed:[11101505](#), PubMed:[25441029](#), PubMed:[8900283](#), PubMed:[9108097](#), PubMed:[9312006](#)). Also promotes a delayed voltage activated potassium current showing outward rectification characteristic (By similarity). During beta-adrenergic receptor stimulation, participates in cardiac repolarization by associating with KCNE1 to form the I(Ks) cardiac potassium current that increases the amplitude and slows down the activation kinetics of outward potassium current I(Ks) (By similarity) (PubMed:[10646604](#), PubMed:[11101505](#), PubMed:[8900283](#), PubMed:[9108097](#), PubMed:[9312006](#)). Muscarinic agonist oxotremorine-M strongly suppresses KCNQ1/KCNE1 current (PubMed:[10713961](#)). When associated with KCNE3, forms the potassium channel that is important for cyclic AMP-stimulated intestinal secretion of chloride ions (PubMed:[10646604](#)). This interaction with KCNE3 is reduced by 17beta-estradiol, resulting in the reduction of currents (By similarity). During conditions of increased substrate load, maintains the driving force for proximal tubular and intestinal sodium ions absorption, gastric acid secretion, and cAMP-induced jejunal chloride ions secretion (By similarity). Allows the provision of potassium ions to the luminal membrane of the secretory canaliculus in the resting state as well as during stimulated acid secretion (By similarity). When associated with KCNE2, forms a heterooligomer complex leading to currents with an apparently instantaneous activation, a rapid deactivation process and a linear current-voltage relationship and decreases the amplitude of the outward current (PubMed:[11101505](#)). When associated with KCNE4, inhibits voltage-gated potassium channel activity (PubMed:[19687231](#)). When associated with KCNE5, this complex only conducts current upon strong and continued depolarization (PubMed:[12324418](#)). Also forms a heterotetramer with KCNQ5; has a voltage-gated potassium channel activity (PubMed:[24855057](#)). Binds with phosphatidylinositol 4,5-bisphosphate (PubMed:[25037568](#)). KCNQ1-KCNE2 channel associates with Na(+)-coupled myo-inositol symporter in the apical membrane of choroid plexus epithelium and regulates the myo- inositol gradient between blood and cerebrospinal fluid with an impact on neuron excitability (By similarity).


## Cellular Location

Cell membrane; Multi-pass membrane protein. Cytoplasmic vesicle membrane Early endosome. Membrane raft. Endoplasmic reticulum Basolateral cell membrane. Apical cell membrane {ECO:0000250|UniProtKB:P97414}; Multi-pass membrane protein. Note=Colocalized with KCNE3 at the plasma membrane (PubMed:10646604). Upon 17beta-oestradiol treatment, colocalizes with RAB5A at early endosome (PubMed:23529131). Heterotetramer with KCNQ5 is highly retained at the endoplasmic reticulum and is localized outside of lipid raft microdomains (PubMed:24855057). During the early stages of epithelial cell polarization induced by the calcium switch, it is removed from the plasma membrane to the endoplasmic reticulum, where it is retained, and redistributed to the basolateral cell surface in a PI3K-dependent manner at a later stage (PubMed:21228319). Colocalizes with SLC5A3 at the apical membrane of choroid plexus epithelium {ECO:0000250|UniProtKB:P97414, ECO:0000269|PubMed:10646604, ECO:0000269|PubMed:21228319, ECO:0000269|PubMed:23529131, ECO:0000269|PubMed:24855057}


## Tissue Location

Abundantly expressed in heart, pancreas, prostate, kidney, small intestine and peripheral blood leukocytes. Less abundant in placenta, lung, spleen, colon, thymus, testis and ovaries

## Images



KCNQ1



Lanes: 100 ug CHO cell lysate

Primary Antibody Dilution: 1:1000

Secondary Antibody: Goat anti-rabbit HRP

Secondary Antibody Dilution: 1:25000

Gene Name: KCNQ1

Submitted by: Anonymous

See Immunoblot 2 Data and Customer Feedback for more information

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.